{"name":"West Japan Thoracic Oncology Group","slug":"west-japan-thoracic-oncology-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Cisplatin+Vindesine+MMC/ concurrent radiation","genericName":"Cisplatin+Vindesine+MMC/ concurrent radiation","slug":"cisplatin-vindesine-mmc-concurrent-radiation","indication":"Locally advanced non-small cell lung cancer (concurrent chemoradiation)","status":"phase_3"},{"name":"Irinotecan+Carboplatin/concurrent radiation","genericName":"Irinotecan+Carboplatin/concurrent radiation","slug":"irinotecan-carboplatin-concurrent-radiation","indication":"Locally advanced non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"Paclitaxel+Carboplatin/concurrent radiation","genericName":"Paclitaxel+Carboplatin/concurrent radiation","slug":"paclitaxel-carboplatin-concurrent-radiation","indication":"Locally advanced non-small cell lung cancer (NSCLC)","status":"phase_3"}]}],"pipeline":[{"name":"Cisplatin+Vindesine+MMC/ concurrent radiation","genericName":"Cisplatin+Vindesine+MMC/ concurrent radiation","slug":"cisplatin-vindesine-mmc-concurrent-radiation","phase":"phase_3","mechanism":"This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms.","indications":["Locally advanced non-small cell lung cancer (concurrent chemoradiation)"],"catalyst":""},{"name":"Irinotecan+Carboplatin/concurrent radiation","genericName":"Irinotecan+Carboplatin/concurrent radiation","slug":"irinotecan-carboplatin-concurrent-radiation","phase":"phase_3","mechanism":"Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue.","indications":["Locally advanced non-small cell lung cancer (NSCLC)"],"catalyst":""},{"name":"Paclitaxel+Carboplatin/concurrent radiation","genericName":"Paclitaxel+Carboplatin/concurrent radiation","slug":"paclitaxel-carboplatin-concurrent-radiation","phase":"phase_3","mechanism":"Paclitaxel and carboplatin chemotherapy combined with concurrent radiation therapy work synergistically to damage cancer cell DNA and inhibit microtubule function, while radiation enhances cytotoxic effects.","indications":["Locally advanced non-small cell lung cancer (NSCLC)","Unresectable stage III NSCLC"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"Taylor & Francis Online","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - Taylor & Francis Online","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQYk82WXJjY0JBdEY4dnRaeUI3eW1MblBOMHJ0aVFEOEE3U3k0dEU4eUo0OWZfVnMxekdfY2RFYzY1bHBxWDFlZGJMZlZRbXpjcUs2cnBVQ242a3ZXUmpXakNLdkRiNFNPenFNS3hZcFU2dDBENTZiWWkybjM3b2xWX0FUcEVJVEFVNFJZMFln?oc=5","date":"2025-09-09","type":"pipeline","source":"Frontiers","summary":"Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody - Frontiers","headline":"Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1nZFZDNkdFUXZlSmo1WF9Hd1FUSERaVFV5VmFCMGRvcTdGXzlNUU5xWl9PZGlNa3A2a2ZoczA1YW9FTE1sYkRaZkNIRlJua0JUSHM3c3VVVkZZZ1M3akZLdDBNU1J0MlBaRUhmQkxDeEVQQnYz?oc=5","date":"2025-03-25","type":"trial","source":"acsjournals.onlinelibrary.wiley.com","summary":"A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G) - acsjournals.onlinelibrary.wiley.com","headline":"A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for co","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1neDF0MXdoeUNQZUw3UjJLTHlyZ0xMc3Brck5PRkc2emtHckM5ZGo2R1N3N3BDNmlOckpkN2swQkVYOTRLeUktVFFNaWV1OWduZkc3UGJxdkNfNTRIQWNF?oc=5","date":"2025-03-22","type":"pipeline","source":"nature.com","summary":"Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC - nature.com","headline":"Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNQXV0UkcxVXotcXNUTlpTb1poZWtJQ3AxRlFRTGRseDRPQnJTRXVkTkFCNW13X1hRZ2NhUG1xcmR6LW95aHJueHQzM0duZjJEOWp2NEdYcUV5bWNfY0ExanM4QVNBWS11d3QwYi02X25NQW80ZTVjRWNrYTktNnVtcXA1aldMcnZIdVVaTA?oc=5","date":"2023-06-30","type":"pipeline","source":"Frontiers","summary":"Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China - Frontiers","headline":"Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBOdmtZVDQtN2M2MTQxRkZzZGVHSVlEbkV6dlJEZGp3UUlEN21nUDBLNUFJd0U0dThSVTFPc1Vmd19UdWE0YmdvMUxOTUNJOWp5NGxsS1hrMWtmZnFPT3U4?oc=5","date":"2023-03-06","type":"pipeline","source":"nature.com","summary":"Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer - nature.com","headline":"Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5xdURkc2ZqWm41aEFKTHkzYWFjTEc2bkFKY0tLclF3MnNMUUY5RjRMUVQ0SkM1bjdyeHczeDU4S2Q2dnNjbUVsaVFkZHhKa2xMN2k0Q1pzZVltazRsZUE?oc=5","date":"2018-09-12","type":"trial","source":"nature.com","summary":"A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L - nat","headline":"A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1qNDlGMHRhaUVsZFNqTXBJVFg2Q1JKcndaTjhfQV9pWXExR0owTGhCWlJSZHJMa1lwZG16Z3NoOGFJX1QzUlJnaEdwSlBIZER5eWE1NFdOM2l4UmN0YW1z?oc=5","date":"2018-05-04","type":"trial","source":"NEJM","summary":"A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung - NEJM","headline":"A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}